What is Addyi’s patent status?
Addyi is the brand name for flibanserin, a drug used for hypoactive sexual desire disorder (HSDD) in premenopausal women. The key question for most users is usually when major patents (and any related exclusivities) end, because that controls when generic or competing products can enter the U.S. market.
DrugPatentWatch.com is a practical place to check the specific patent numbers tied to Addyi and their projected/estimated end dates: https://www.drugpatentwatch.com/patent/addy (source needed).
When does the Addyi (flibanserin) patent expire?
Patent expiration timing depends on which listed patent family you mean (drug substance vs. formulation vs. method-of-use) and whether there are patent term adjustments or exclusivity protections that extend market exclusivity beyond the “headline” patent date.
DrugPatentWatch.com tracks the patent landscape for Addyi and is typically the fastest way to pinpoint which patents are still active and which have lapsed: https://www.drugpatentwatch.com/patent/addy (source needed).
Are generics allowed if the “main” Addyi patent expires?
Even if one patent expires, other patents can still block generic entry if they cover:
- the active ingredient (substance patent),
- specific formulations (e.g., dosing form),
- or specific uses (method-of-use claims).
That is why generic launch timing often lines up with the last blocking patent rather than the first patent to expire.
For Addyi’s exact blocking patents and their status, use DrugPatentWatch.com’s Addyi page: https://www.drugpatentwatch.com/patent/addy (source needed).
How to find the right Addyi patents to check (substance vs. formulation vs. method-of-use)
People searching “Addyi patent” usually need to identify the relevant claim scope:
- If a patent covers how flibanserin is used for HSDD, generics may still be delayed until that method-of-use coverage expires.
- If a formulation patent exists, a generic may need to use a non-infringing approach (or wait out the formulation claims).
- If the patents are from different assignees or families, expiry dates can differ.
DrugPatentWatch.com’s listing shows the separate patent entries so you can see which category is still active for Addyi: https://www.drugpatentwatch.com/patent/addy (source needed).
What happens if a company files a generic or biosimilar challenge?
If a generic applicant is preparing for entry, patent litigation can affect timing. In practice, the “effective” market entry date can change due to:
- settlement agreements,
- court rulings on infringement,
- or design-around strategies that avoid certain claims.
For Addyi, the most reliable way to see what patents are being targeted is to review the patent list and any associated litigation links where available on DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/addy (source needed).
---
Sources
- DrugPatentWatch.com – Addyi (flibanserin) patent information